A "functionalized congener" approach to adenosine receptor antagonists has provided a means to synthesize highly potent peptide conjugates of 1,3-dialkylxanthines. The antagonist XAC, such a functionalized xanthine amine congener, has been attached to a segment derived from the neurotransmitter peptide substance P (SP) to form a binary drug that binds to both receptors with K i values of 35 nM (central A 1 -adenosine) and 300 nM (striatal SP). Coupling of the functionalized adenosine agonist N 6 -[p-(carboxymethyl)phenyl]adenosine to an SP C-terminal peptide also resulted in a binary drug that binds to both receptors. The demonstration that the biochemical properties of two unrelated drugs, both of which act through binding at extracellular receptors, may be combined in the same molecule suggests a novel strategy for drug design. In principle, a combined effect of the two different substances that produce the same final effect (e.g., hypotension by adenosine agonists and by SP analogues) might occur in vivo. Adenosine analogues have analgesic properties, and the binary drug derived from substance P and adenosine agonists or antagonists might provide useful tools for probing interrelationships of SP pathways and sites for the antinociceptive action of adenosine.A "functionalized congener" approach to adenosine receptor antagonists 1,2 has resulted in highly potent 1,3-dialkylxanthines having amino and carboxylic acid functionalized chains. These functional groups have been coupled covalently to amino acids and dipeptides. The resulting amino acid and oligopeptide conjugates have full, and in some cases enhanced, biological activity. In our previous work 2 we used nonhormonal peptide sequences to alter the physicochemical properties of the drugs. We now report the attachment of a xanthine to a segment derived from a putative neurotransmitter peptide, substance P (SP) (reviews, ref 3,4), to form a binary drug 1 (Figure 1). This drug binds both to adenosine receptors and to substance P receptors with affinity comparable to that of each component at the appropriate receptor. In addition, coupling of the adenosine agonist N 6 -[p-(carboxymethyl)phenyl]adenosine, 5 2a, to substance P segment 7-11 produced the binary drug 3, which also binds to both receptors. We have demonstrated a potentially general strategy via "functionalized congeners" for the synthesis of binary drugs that combine pharmacological properties of both elements. The choice of combination of adenosine receptor ligands and substance P in target molecules stems from the peripheral hypotensive effect elicited by agonists for both receptor. 6,7 Moreover, since both receptors mediate central nociceptive effect, 8,9 the binary conjugates may prove to be useful tools in probing neuronal pathways involved in perception of pain.
ResultsThe xanthine amine congener (XAC) has several features in its structure that lead to enhanced receptor affinities. Thus, we have found from a study of many xanthine derivatives that an amino group in the appended chain...